Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587067 | 0.78 | GAA (0.42) | MAPTGAANOS2HTTKDM4E | |
| SCHEMBL251666 | 0.77 | GAA (0.41) | MAPTGAA | |
| SCHEMBL2255782 | 0.74 | MAPT (0.50) | MAPTGAANOS2SMN1; SMN2RAB9A | |
| SCHEMBL29789697 | 0.74 | MAPT (0.50) | MAPTGAANOS2SMN1; SMN2RAB9A | |
| SCHEMBL6607968 | 0.71 | GAA (0.46) | MAPTGAANOS2KDM4EHPGD | |
| SCHEMBL1726909 | 0.71 | GAA (0.46) | MAPTGAANOS2KDM4EHPGD | |
| SCHEMBL1285713 | 0.71 | MAPT (0.46) | MAPTGAANOS2HTTSMN1; SMN2 | |
| SCHEMBL21145451 | 0.71 | GAA (0.46) | MAPTGAANOS2KDM4EHPGD | |
| SCHEMBL27889582 | 0.70 | MAPT (0.42) | MAPTGAASMN1; SMN2RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL6991456 | 0.69 | MAPT (0.41) | MAPTGAANOS2SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534516-B1 | Method of affecting androgen receptor activity comprising the in vivo administration of a composition | LIGAND PHARMACEUTICALS INCORPORATED | 2003-03-18 | — | — | US | disclosed |
| EP-0918774-B9 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-0918774-B1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6017924-A | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0918774-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997049709-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-31 | — | — | WO | disclosed |